Published in AIDS Weekly, September 22nd, 1997
What the studies in the September 4, 1997, issue of the New England Journal of Medicine did not address was how most of the millions of people around the world infected with HIV could afford the estimated $10,000 to $12,000 annual treatment.
The three drugs involved in the cocktail are: indinavir, sold under the brand name Crixivan by Merck & Co. Inc.; lamivudine, sold as Epivir or 3TC by Glaxo-Wellcome Plc, and another Glaxo product, AZT, known as zidovudine or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.